Cargando…

Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation

SIMPLE SUMMARY: Metastatic renal cell carcinoma continues to have a poor prognosis. Chemotherapies and immuno-oncologic therapies have garnered increasing importance in cancer therapy, with improvements in patient care and survival. However, a large proportion of patients present with tumors resista...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenberg, Jacob W., Kim, Hogyoung, Ahn, Miae, Moustafa, Ahmed A., Zhou, He, Barata, Pedro C., Boulares, A. Hamid, Abdel-Mageed, Asim B., Krane, Louis S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870174/ https://www.ncbi.nlm.nih.gov/pubmed/35205655 http://dx.doi.org/10.3390/cancers14040903

Ejemplares similares

Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma
por: Greenberg, Jacob W., et al.
Publicado: (2021)

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
por: Ho, Alan L., et al.
Publicado: (2021)

Tipifarnib in the treatment of acute myeloid leukemia
por: Thomas, Xavier, et al.
Publicado: (2007)

Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells
por: Krzykowska-Petitjean, Katarzyna, et al.
Publicado: (2011)

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma
por: Alonso-Alonso, Ruth, et al.
Publicado: (2020)

Latent HIV-Exosomes Induce Mitochondrial Hyperfusion Due to Loss of Phosphorylated Dynamin-Related Protein 1 in Brain Endothelium
por: Chandra, Partha K., et al.
Publicado: (2021)

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Tipifarnib prevents development of hypoxia-induced pulmonary hypertension
por: Duluc, Lucie, et al.
Publicado: (2017)

Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion
por: Kim, Hogyoung, et al.
Publicado: (2016)

Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis
por: Kim, Hogyoung, et al.
Publicado: (2015)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia
por: Raponi, Mitch, et al.
Publicado: (2004)

High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer
por: Datta, Amrita, et al.
Publicado: (2018)

A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors
por: DING, NING, et al.
Publicado: (2014)

Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer
por: Khurana, Namrata, et al.
Publicado: (2017)

Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
por: Jawad, Mays, et al.
Publicado: (2012)

Molecular mechanisms of penile traction for penile rehabilitation in a bilateral cavernous nerve crush injury rat model
por: Dick, Brian, et al.
Publicado: (2023)

Molecular characterization of exosome-like vesicles from breast cancer cells
por: Kruger, Stefan, et al.
Publicado: (2014)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

Circulating Plasma Exosomal Proteins of Either SHIV-Infected Rhesus Macaque or HIV-Infected Patient Indicates a Link to Neuropathogenesis
por: Chandra, Partha K., et al.
Publicado: (2023)

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance
por: Rausch, Magdalena, et al.
Publicado: (2020)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism
por: Sourdon, Joevin, et al.
Publicado: (2017)

Antitumor effects of low‐dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF‐1α‐expressing gastric cancer cells
por: Egawa, Noriyuki, et al.
Publicado: (2021)

Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis
por: He, Ying, et al.
Publicado: (2021)

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005)

The Nrf1 and Nrf2 Balance in Oxidative Stress Regulation and Androgen Signaling in Prostate Cancer Cells
por: Schultz, Michelle A., et al.
Publicado: (2010)

Effective Antiviral Activity of the Tyrosine Kinase Inhibitor Sunitinib Malate against Zika Virus
por: Lin, Chen-Sheng, et al.
Publicado: (2021)

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
por: Sbitti, Yassir, et al.
Publicado: (2018)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Metastatic Perivascular Epithelioid Cell Tumor Of The Kidney: A Case Report With Emphasis On Response To The Tyrosine-Kinase Inhibitor Sunitinib
por: AlAzab, Rami S, et al.
Publicado: (2019)

HIGH FAT DIET INDUCES LUNG REMODELING IN APOE DEFICIENT MICE: AN ASSOCIATION WITH AN INCREASE IN CIRCULATORY AND LUNG INFLAMMATORY FACTORS
por: Naura, Amarjit S., et al.
Publicado: (2009)

Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells
por: Srivastava, Akhil, et al.
Publicado: (2016)

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma
por: Polena, Helena, et al.
Publicado: (2018)

Overcome the barriers of the skin: exosome therapy
por: Yang, Gi Hoon, et al.
Publicado: (2021)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant
por: Tsuruda, Masafumi, et al.
Publicado: (2020)

The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study
por: Bernard, Valérie, et al.
Publicado: (2016)

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
por: Huang, Qiang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s0jaqu1g6qnrdunnh7sc2k5nh9